First Trust Advisors LP Reduces Stock Holdings in Axon Enterprise, Inc $AXON

First Trust Advisors LP reduced its position in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 25.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 115,893 shares of the biotechnology company’s stock after selling 39,390 shares during the quarter. First Trust Advisors LP owned 0.15% of Axon Enterprise worth $95,953,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Banque Transatlantique SA bought a new stake in Axon Enterprise during the first quarter valued at approximately $31,000. Flaharty Asset Management LLC purchased a new position in shares of Axon Enterprise during the 1st quarter worth $33,000. Hemington Wealth Management grew its position in shares of Axon Enterprise by 70.8% during the 2nd quarter. Hemington Wealth Management now owns 41 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 17 shares during the period. Whipplewood Advisors LLC increased its stake in shares of Axon Enterprise by 192.9% in the 2nd quarter. Whipplewood Advisors LLC now owns 41 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Finally, NewSquare Capital LLC raised its holdings in Axon Enterprise by 96.2% in the 2nd quarter. NewSquare Capital LLC now owns 51 shares of the biotechnology company’s stock worth $42,000 after purchasing an additional 25 shares during the period. Institutional investors own 79.08% of the company’s stock.

Wall Street Analyst Weigh In

AXON has been the topic of several analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday. Royal Bank Of Canada started coverage on Axon Enterprise in a research note on Monday, November 17th. They set an “outperform” rating and a $860.00 price objective for the company. Wall Street Zen lowered shares of Axon Enterprise from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Cowen reaffirmed a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Finally, The Goldman Sachs Group dropped their price target on shares of Axon Enterprise from $940.00 to $800.00 and set a “buy” rating for the company in a research report on Wednesday, November 5th. Fourteen investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Axon Enterprise currently has an average rating of “Moderate Buy” and an average target price of $815.00.

Axon Enterprise Stock Up 0.1%

NASDAQ AXON opened at $550.95 on Friday. Axon Enterprise, Inc has a 12 month low of $469.24 and a 12 month high of $885.91. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57. The stock has a market cap of $43.48 billion, a PE ratio of 174.35, a P/E/G ratio of 126.46 and a beta of 1.40. The stock’s 50 day moving average is $639.29 and its 200 day moving average is $720.29.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 10.05% and a return on equity of 4.29%. The company’s quarterly revenue was up 30.6% compared to the same quarter last year. During the same period last year, the business earned $1.45 earnings per share. Research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 100 shares of Axon Enterprise stock in a transaction on Thursday, September 11th. The shares were sold at an average price of $752.54, for a total value of $75,254.00. Following the sale, the director directly owned 1,416 shares in the company, valued at approximately $1,065,596.64. The trade was a 6.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, President Joshua Isner sold 2,041 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $535.11, for a total transaction of $1,092,159.51. Following the transaction, the president directly owned 269,502 shares of the company’s stock, valued at $144,213,215.22. This trade represents a 0.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 42,459 shares of company stock valued at $28,485,977 in the last ninety days. Corporate insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.